Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Renata Glehn-Ponsirenas has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Elevations in Donor-Derived Cell-Free DNA and Allograft Outcomes in Kidney Transplantation

    by Jeffrey A. Klein, David Taber, David Wojciechowski, Didier A. Mandelbrot, Renata Glehn-Ponsirenas, Oyedolamu Olaitan, Pranjal Jain, James Lu, Martina M. McGrath, Mohanram Narayanan, et al.

    Key Points: We assessed whether an initial donor-derived cell-free DNA elevation during routine surveillance was associated with allograft dysfunction and loss in kidney transplant recipients. Intermediate and high donor-derived cell-free DNA states were independently associated with 3.7-fold and 6.4-fold higher risks of allograft loss, respectively. Persistently low donor-derived cell-free DNA levels were associated with low rates of rejection and allograft loss, identifying a low-risk population. Background: Although donor-derived cell-free DNA (dd-cfDNA) correlates with histologic rejection and injury severity, its association with long-term graft outcomes has yet to be well established in kidney transplant recipients. We hypothesize that among patients monitored with dd-cfDNA, an initial elevation may be associated with subsequent allograft dysfunction and loss. Methods: The Kidney Allograft Outcomes AlloSure Registry is a prospective, multicenter cohort of 1743 adult kidney transplant recipients from 56 US centers; this analysis included 1258 patients who initiated dd-cfDNA surveillance 15–60 days post-transplant with up to 3-year follow-up. A multistate model was applied to characterize transitions from a low dd-cfDNA state (no elevations) to intermediate (0.5%–1.0% with ≥61% relative change value) or high (≥1.0%) dd-cfDNA states, and their unadjusted and covariate-adjusted associations with allograft loss or all-cause death were quantified using hazard regression models. Results: Within 3 years, 36% of patients transitioned to an elevated dd-cfDNA state (intermediate n =216; high n =233). Allograft dysfunction by 36 months occurred significantly more often in patients with dd-cfDNA elevations despite preserved allograft function at the time of elevation (eGFR ≥60 ml/min per 1.73 m 2 in 42% of intermediate and 33% of high), consistent with subclinical injury. Transitions from low to elevated dd-cfDNA states were strongly associated with subsequent allograft loss (adjusted hazard ratios, 3.70 [95% confidence interval [CI], 1.38 to 9.90] for intermediate; 6.36 [95% CI, 2.80 to 14.42] for high), while mortality did not differ by dd-cfDNA state. Conclusions: Initial dd-cfDNA elevations exceeding established thresholds were independently associated with higher risks of allograft dysfunction and loss across both elevation categories, whereas patients who remained in the low dd-cfDNA state experienced favorable outcomes.


  • Top Cited Papers
    Open Access

    Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies

    by Jonathan S. Bromberg, Daniel C. Brennan, David J. Taber, Matthew Cooper, Sanjiv Anand, Enver Akalin, Edmund Huang, Jeffrey A. Klein, Renata Glehn-Ponsirenas, Jeffrey Rogers, et al.


  • Open Access

    Donor-derived cell-free DNA testing in pediatric kidney transplant recipients: indications and clinical utility

    by Jayanthi Chandar, Vaka Sigurjonsdottir, Marissa Defreitas, Tara Gavcovich, Mingming Zhou, Renata Glehn-Ponsirenas, George Burke

    Background: We describe our single-center experience in performing donor-derived cell-free DNA (dd-cfDNA) testing for a clinical indication in pediatric kidney transplant recipients. Methods: Dd-cfDNA was done for increase in creatinine, appearance of de novo anti-HLA antibodies (dnHLAab) and for a clinical indication. We compared clinical characteristics of patients with dd-cfDNA > 1 with those with dd-cfDNA ≤ 1 and also compared dd-cfDNA in patients with no biopsy proven rejection (BPAR) or dnHLAab with those with BPAR, and those with dnHLAab and no BPAR. Results: Chart review was performed in 106 patients with a mean age of 11.0 ± 5.5 years. When compared with 62 patients with dd-cfDNA ≤ 1, 59.0% (26/44) of patients with dd-cfDNA > 1 had BPAR (OR 13.5: 95%CI 4.6,38; p < 0.0001), and 88.1% (37/44) had dnHLAab (OR 60.3 95%CI 17.2,192.2; p < 0.0001). Patients with DQ and DR dnHLAab (OR 115.2: 95%CI 24.8, 509.5; p < 0.0001) and those with donor-specific antibodies (DSAs) (OR 50.8: 95%CI 13.0, 168.7; p < 0.0001) were likely to have dd-cfDNA > 1. A repeated measures linear mixed effect model revealed a significant difference in dd-cfDNA between those with no antibodies or BPAR (p < 0.0001) and patients with BPAR and dnHLAab, with or without DSA. At the end of the follow-up period, eGFR was 72 mL/min/1.73 m2 in those without BPAR or dnHLAab and was significantly different from those with BPAR (eGFR 51 mL/min/1.73 m2 (p < 0.0001). Conclusions: Elevated dd-cfDNA is strongly associated with BPAR, class II dnHLAab and DSAs. Conversely, low values are observed in immunoquiescent states. Dd-cfDNA can be a useful tool for non-invasive clinical decision-making. Graphical


  • Open Access

    Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant

    by Joao Manzi, Camilla O. Hoff, Raphaella Ferreira, Renata Glehn-Ponsirenas, Gennaro Selvaggi, Akin Tekin, Christopher B. O’brien, Lynn Feun, Rodrigo Vianna, Phillipe Abreu

    The liver is the world’s sixth most common primary tumor site, responsible for approximately 5% of all cancers and over 8% of cancer-related deaths. Hepatocellular carcinoma (HCC) is the predominant type of liver cancer, accounting for approximately 75% of all primary liver tumors. A major therapeutic tool for this disease is liver transplantation. Two of the most significant issues in treating HCC are tumor recurrence and graft rejection. Currently, the detection and monitoring of HCC recurrence and graft rejection mainly consist of imaging methods, tissue biopsies, and alpha-fetoprotein (AFP) follow-up. However, they have limited accuracy and precision. One of the many possible components of cfDNA is circulating tumor DNA (ctDNA), which is cfDNA derived from tumor cells. Another important component in transplantation is donor-derived cfDNA (dd-cfDNA), derived from donor tissue. All the components of cfDNA can be analyzed in blood samples as liquid biopsies. These can play a role in determining prognosis, tumor recurrence, and graft rejection, assisting in an overall manner in clinical decision-making in the treatment of HCC.


  • Open Access

    336.3: Clinical Utility of Donor-Derived Cell-Free DNA During the Period of Recovery of Renal Function After Kidney Transplantation

    by Yasmim Dreige, Giovanna Lima, Marina Cristelli, Mônica Nakamura, Renato Foresto, Paulo Pierry, Renata Glehn-Ponsirenas, José Levi, Jose Medina-Pestana, Helio Tedesco-Silva

  • Open Access

    High levels of donor-derived cell-free DNA in a case of graft-versus-host-disease following liver transplantation

    by Duncan Lewis, Renata Glehn-Ponsirenas, Natali Gulbahce, Leah J. Hooey, Joanna M. Chaffin, Jake Miles, Robert Woodward, Sergio Duarte, Thiago Beduschi, Ali Zarrinpar


  • Open Access

    Anti-HLA Donor-Specific IgG Subclasses and C1q-binding Evolution in Posttransplant Monitoring

    by Renata von Glehn Ponsirenas, Helena B. Msc Cazarote, Stanley de Almeida Md Araújo, David Campos Md Wanderley, Silvia Shimakura, Joana S. Bs Valdameri, Fabiana L. C. Contieri, Cristina C. Q. C. von Glehn, Michelle F. Susin, Vanessa Santos Sotomaior

    Background The identification of low-level antibodies by single-antigen bead methodology has brought advancements to risk evaluation of kidney transplant recipients. However, the use of mean fluorescence intensity (MFI) to quantify antibodies and to guide therapy is not enough. Notably, immunoglobulin G (IgG) subclass switching is hypothesized to follow a programmed sequence after an emergency signal from the germinal center. In transplantation this process is not clear yet. In the present study, we sequentially evaluate anti-HLA donor specific antibody (DSA) subclasses, their profile changes, and C1q-binding ability and the influence of those characteristics on antibody mediated rejection (AMR) occurrence and allograft function. Methods A total of 30 DSA-positive patients were tested for IgG subclass content and C1q-binding in sequential serum samples. Results Twenty-one patients were DSA-positive before transplant; patients sensitized only by transfusion or pregnancies had IgG1 and/or IgG3, and patients sensitized by both transfusion and pregnancies or previous transplant showed a broader range of IgG subclasses. C1q binding was detected in high MFI made up of IgG1 or multiple IgG subclasses. Only 4 patients were positive for C1q posttransplantation and 3 of these showed an increase in MFI, changes in subclasses patterns, AMR, and allograft dysfunction. Conclusions Posttransplant evaluation of DSA subclasses and the ability to bind C1q may be informative for both AMR occurrence and allograft dysfunction. Monitoring these events may help to better define risk and interventional time points.


  • Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure

    by Helena B. Cazarote, Silvia Shimakura, Joana S. Valdameri, Fabiana L.C. Contieri, Cristina Q.C. von Glehn, Carlos M. Aita, Michelle F. Susin, Vanessa Santos Sotomaior, Renata Glehn-Ponsirenas